• Ascelia Pharma said CFO Anton Hansson will leave the company, as it moves to cut its cost base.
• Hansson will stay in the role until late August 2026.
• The finance function will report directly to CEO Magnus Corfitzen following the departure.
• Management changes align resources toward FDA interactions, including an upcoming Type A meeting tied to the path forward for Orviglance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.